SCHEMBL210811

SCHEMBL210811

Nc1ccccc1NC(=O)c1ccc(C(N)c2cccnc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 20/20 0.66
HDAC3 O15379 10/20 0.66
HDAC2 Q92769 10/20 0.66
NAMPT P43490 3/20 0.55
HDAC4 P56524 3/20 0.54
HDAC7 Q8WUI4 3/20 0.54
HDAC10 Q969S8 3/20 0.54
HDAC11 Q96DB2 3/20 0.54
HDAC8 Q9BY41 3/20 0.54
HDAC6 Q9UBN7 3/20 0.54
HDAC9 Q9UKV0 3/20 0.54
HDAC5 Q9UQL6 3/20 0.54
EPHA2 P29317 1/20 0.54
MAPK1 P28482 1/20 0.54
NCOR2 Q9Y618 5/20 0.53
KDM1A O60341 1/20 0.53
CYP3A4 P08684 1/20 0.53
F3 P13726 1/20 0.53
ABL1 P00519 1/20 0.52
PDGFRB P09619 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1064065 0.81 HDAC1 (0.60) HDAC1HDAC3HDAC2HDAC4HDAC7
SCHEMBL3229396 0.81 HDAC1 (0.68) HDAC1HDAC3HDAC2NAMPTHDAC4
SCHEMBL3939284 0.80 HDAC1 (0.56) HDAC1HDAC3HDAC2NAMPTHDAC4
SCHEMBL3938681 0.80 HDAC1 (0.64) HDAC1HDAC3HDAC2NAMPTHDAC4
SCHEMBL18086514 0.80 HDAC1 (1.00) HDAC1HDAC3HDAC2HDAC4HDAC7
SCHEMBL2414608 0.79 HDAC1 (0.59) HDAC1HDAC3HDAC2NAMPTHDAC4
SCHEMBL2414606 0.79 HDAC1 (0.59) HDAC1HDAC3HDAC2NAMPTHDAC4
SCHEMBL2415859 0.79 HDAC1 (0.59) HDAC1HDAC3HDAC2NAMPTHDAC4
SCHEMBL13110753 0.79 HDAC1 (0.54) HDAC1HDAC3HDAC2NAMPTHDAC4
SCHEMBL13110986 0.79 HDAC1 (0.54) HDAC1HDAC3HDAC2NAMPTHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-20050245518-A1 Antiproliferative agents METHYLGENE, INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 HDAC1 1/4885HDAC3 4/4885HDAC2 10/4885
US-20050245518-A1 Antiproliferative agents HDAC1, HDAC11, HDAC5 HDAC1 1/4885HDAC3 5/4885HDAC2 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.